<- Go Home
Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.
Market Cap
$716.5M
Volume
132.4K
Cash and Equivalents
$118.8M
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$18.38
52 Week Low
$5.34
Dividend
N/A
Price / Book Value
2.58
Price / Earnings
-8.65
Price / Tangible Book Value
2.58
Enterprise Value
$597.8M
Enterprise Value / EBITDA
N/A
Operating Income
-$61.6M
Return on Equity
51.71%
Return on Assets
-32.74
Cash and Short Term Investments
$118.8M
Debt
N/A
Equity
$114.7M
Revenue
N/A
Unlevered FCF
N/A
Sector
Biotechnology
Category
N/A